Xiangji Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiangji Wu has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Hao Kong
State Key Laboratory of Biotherapy, Department of Biotherapy, West China Hospital, Sichuan University, Chengdu, China
74 shared publications - Hong Jiang
West China Hospital of Sichuan University
74 shared publications - Lu Chen
Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China
50 shared publications - Ping Wang
State Key Laboratory of Biotherapy, Department of Biotherapy, West China Hospital, Sichuan University, Chengdu, China
50 shared publications - Qingxin Yang
Center of Infectious Diseases and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University
50 shared publications - Chunwei Wu
Department of Pancreatic Surgery, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China
39 shared publications
Latest Publications
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Spatial Context of Immune Checkpoints as Predictors of Overall Survival in Patients with Resectable Colorectal Cancer Independent of Standard Tumor–Node–Metastasis Stages
Table S3 from Spatial Context of Immune Checkpoints as Predictors of Overall Survival in Patients with Resectable Colorectal Cancer Independent of Standard Tumor–Node–Metastasis Stages
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Spatial Context of Immune Checkpoints as Predictors of Overall Survival in Patients with Resectable Colorectal Cancer Independent of Standard Tumor–Node–Metastasis Stages
Table S3 from Spatial Context of Immune Checkpoints as Predictors of Overall Survival in Patients with Resectable Colorectal Cancer Independent of Standard Tumor–Node–Metastasis Stages
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from Spatial Context of Immune Checkpoints as Predictors of Overall Survival in Patients with Resectable Colorectal Cancer Independent of Standard Tumor–Node–Metastasis Stages
Clinical characteristics of training and validation cohorts
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Spatial Context of Immune Checkpoints as Predictors of Overall Survival in Patients with Resectable Colorectal Cancer Independent of Standard Tumor–Node–Metastasis Stages
Clinical characteristics of training and validation cohorts
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Spatial Context of Immune Checkpoints as Predictors of Overall Survival in Patients with Resectable Colorectal Cancer Independent of Standard Tumor–Node–Metastasis Stages
Analysis of immune cell statuses across different tumor locations in training and validation cohorts.
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Spatial Context of Immune Checkpoints as Predictors of Overall Survival in Patients with Resectable Colorectal Cancer Independent of Standard Tumor–Node–Metastasis Stages
Analysis of immune cell statuses across different tumor locations in training and validation cohorts.
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Spatial Context of Immune Checkpoints as Predictors of Overall Survival in Patients with Resectable Colorectal Cancer Independent of Standard Tumor–Node–Metastasis Stages
Immune cell status changes after αPD-1 + αTIM-3 treatment
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Spatial Context of Immune Checkpoints as Predictors of Overall Survival in Patients with Resectable Colorectal Cancer Independent of Standard Tumor–Node–Metastasis Stages
Immune cell status changes after αPD-1 + αTIM-3 treatment
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Spatial Context of Immune Checkpoints as Predictors of Overall Survival in Patients with Resectable Colorectal Cancer Independent of Standard Tumor–Node–Metastasis Stages
Pearson correlation of screened factors
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Spatial Context of Immune Checkpoints as Predictors of Overall Survival in Patients with Resectable Colorectal Cancer Independent of Standard Tumor–Node–Metastasis Stages
Pearson correlation of screened factors
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Spatial Context of Immune Checkpoints as Predictors of Overall Survival in Patients with Resectable Colorectal Cancer Independent of Standard Tumor–Node–Metastasis Stages
Comparative analysis of CD8+ cell subtypes distribution across spatial clusters in unsupervised groupings
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Spatial Context of Immune Checkpoints as Predictors of Overall Survival in Patients with Resectable Colorectal Cancer Independent of Standard Tumor–Node–Metastasis Stages
Comparative analysis of CD8+ cell subtypes distribution across spatial clusters in unsupervised groupings
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Spatial Context of Immune Checkpoints as Predictors of Overall Survival in Patients with Resectable Colorectal Cancer Independent of Standard Tumor–Node–Metastasis Stages
Table S1 from Spatial Context of Immune Checkpoints as Predictors of Overall Survival in Patients with Resectable Colorectal Cancer Independent of Standard Tumor–Node–Metastasis Stages
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Spatial Context of Immune Checkpoints as Predictors of Overall Survival in Patients with Resectable Colorectal Cancer Independent of Standard Tumor–Node–Metastasis Stages
Table S1 from Spatial Context of Immune Checkpoints as Predictors of Overall Survival in Patients with Resectable Colorectal Cancer Independent of Standard Tumor–Node–Metastasis Stages
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Spatial Context of Immune Checkpoints as Predictors of Overall Survival in Patients with Resectable Colorectal Cancer Independent of Standard Tumor–Node–Metastasis Stages
Clinical characteristics of patients from TMA study
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Spatial Context of Immune Checkpoints as Predictors of Overall Survival in Patients with Resectable Colorectal Cancer Independent of Standard Tumor–Node–Metastasis Stages
Clinical characteristics of patients from TMA study
- Open Access
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Table S5 from Spatial Context of Immune Checkpoints as Predictors of Overall Survival in Patients with Resectable Colorectal Cancer Independent of Standard Tumor–Node–Metastasis Stages
Spatial phenotypes of CD8+ T cells
- 16 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Spatial Context of Immune Checkpoints as Predictors of Overall Survival in Patients with Resectable Colorectal Cancer Independent of Standard Tumor–Node–Metastasis Stages
Spatial phenotypes of CD8+ T cells